Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | suspended | Phase 2 / Phase 3 | 138 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | suspended | Phase 2 / Phase 3 | 1,122 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | suspended | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06325683 | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | suspended | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06876142 | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | suspended | Phase 1 / Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma | suspended | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | suspended | Phase 1 / Phase 2 | 50 | City of Hope Medical CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | suspended | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06039202 | CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer | suspended | Phase 2 | 100 | Holy Stone Healthcare Co., LtdINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer | suspended | Phase 2 / Phase 3 | 928 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06868238 | Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) | suspended | Phase 2 | 30 | University of FloridaOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 33 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | suspended | Phase 1 / Phase 2 | 100 | University of ChicagoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma | suspended | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease | suspended | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06329570 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 / Phase 2 | 10 | NaviFUS CorporationINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy | suspended | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 88 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 613 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | suspended | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | suspended | Phase 2 | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | suspended | Phase 2 | 63 | Duke UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | suspended | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | suspended | Phase 2 | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | suspended | Phase 2 | 236 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05494697 | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC | suspended | Phase 2 | 90 | AIM ImmunoTech Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05607407 | Methimazole in Patients With Progressive Glioblastoma | suspended | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | suspended | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03164460 | Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer | suspended | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA | suspended | Phase 2 | 133 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | suspended | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | suspended | Phase 2 / Phase 3 | 189 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | suspended | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) | suspended | Phase 2 | 90 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07377526 | TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | suspended | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01876771 | A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | suspended | Phase 2 | 413 | AHS Cancer Control AlbertaOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | suspended | Phase 1 / Phase 2 | 47 | Roswell Park Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer | suspended | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | suspended | Phase 1 / Phase 2 | 66 | Hackensack Meridian HealthOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04585477 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | suspended | Phase 2 | 80 | Stanford UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials